# Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

> **NCT04292899** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 4891 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Remdesivir
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT04292899
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-06
- **Primary completion:** 2020-04-09
- **Final completion:** 2020-06-30
- **Target enrollment:** 4891 (ACTUAL)
- **Last updated:** 2020-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04292899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04292899, "Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04292899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*